Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results